 | Up a level |
Janssen, J J W M; Löwenberg, B; Manz, M; Biemond, B J; Westerweel, P E; Klein, S K; Fehr, M; Sinnige, H A M; Efthymiou, A; Legdeur, M C J C; Pabst, T; Gregor, M; van der Poel, M W M; Deeren, D; Tick, L W; Jongen-Lavrencic, M; van Obbergh, F; Boersma, R S; de Weerdt, O; Chalandon, Y; ... (2022). Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome. Leukemia, 36(9), pp. 2189-2195. Nature Publishing Group 10.1038/s41375-022-01657-3
Zander, T; Aebi, Stefan; Pabst, T; Renner, C; Driessen, C (2017). Spotlight on pomalidomide: could less be more? Leukemia, 31(9), pp. 1987-1989. Nature Publishing Group 10.1038/leu.2017.156
O'Meara, A; Pabst, T; Heim, D; Gerull, S; Bucher, C; Halter, J; Arber, C; Rovò, A; Tichelli, A; Gratwohl, A; Stern, M (2011). High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML. Bone marrow transplantation, 46(5), pp. 636-40. London: Nature Publishing Group 10.1038/bmt.2010.181
Raschle, J; Ratschiller, D; Mans, S; Mueller, B U; Pabst, T (2011). High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. British journal of cancer, 105(7), pp. 970-4. Basingstoke: Nature Publishing Group 10.1038/bjc.2011.329
Bonadies, N; Neururer, Ch; Steege, A; Vallabhapurapu, S; Pabst, T; Mueller, B U (2010). PU.1 is regulated by NF-kappaB through a novel binding site in a 17 kb upstream enhancer element. Oncogene, 29(7), pp. 1062-72. Basingstoke, UK: Nature Publishing Group 10.1038/onc.2009.371
Eyholzer, M; Schmid, S; Wilkens, L; Mueller, B U; Pabst, T (2010). The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. British journal of cancer, 103(2), pp. 275-84. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6605751
Taverna, C; Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C (2010). Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss medical weekly, 140, w13054. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2010.13054
Pabst, T; Eyholzer, M; Fos, J; Mueller, B U (2009). Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. British journal of cancer, 100(8), pp. 1343-6. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6604977
Pabst, T; Mueller, B U (2007). Transcriptional dysregulation during myeloid transformation in AML. Oncogene, 26(47), pp. 6829-37. Basingstoke, UK: Nature Publishing Group 10.1038/sj.onc.1210765
Pabst, T; Fontana, S; Groebli, R; Leibundgut, K; Zwicky, C; Taleghani, BM (2006). Progenitor cell recruitment during individualized high-flow, very-large-volume apheresis for autologous transplantation improves collection efficiency. Transfusion, 46(8), pp. 1408-16. Malden, Mass.: Wiley-Blackwell 10.1111/j.1537-2995.2006.00910.x
Mueller, B U; Pabst, T; Hauser, P; Gilliland, G; Neuberg, D; Tenen, D G (2006). Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemia. British journal of cancer, 94(12), pp. 1918-20. Basingstoke: Nature Publishing Group 10.1038/sj.bjc.6603198
Mueller, B U; Buerger, A U; Solenthaler, M; Garamvoelgyi, E M; Oppliger-Leibundgut, E; Fey, M F; Pabst, T (2006). Pleural tumors as sole primary manifestation of acute promyelocytic leukemia. Annals of oncology, 17(4), pp. 722-3. Oxford: Oxford University Press 10.1093/annonc/mdj062
